Sanchez Teresa
Department of Pathology and Laboratory Medicine, Center for Vascular Biology, Weill Cornell Medical College, 1300 York Ave, Room A607B/Box 69, New York, NY, 10065, USA.
Curr Atheroscler Rep. 2016 Jun;18(6):31. doi: 10.1007/s11883-016-0586-1.
Numerous preclinical studies indicate that sustained endothelial activation significantly contributes to tissue edema, perpetuates the inflammatory response, and exacerbates tissue injury ultimately resulting in organ failure. However, no specific therapies aimed at restoring endothelial function are available as yet. Sphingosine-1-phosphate (S1P) is emerging as a potent modulator of endothelial function and endothelial responses to injury. Recent studies indicate that S1PR are attractive targets to treat not only disorders of the arterial endothelium but also microvascular dysfunction caused by ischemic or inflammatory injury. In this article, we will review the current knowledge of the role of S1P and its receptors in endothelial function in health and disease, and we will discuss the therapeutic potential of targeting S1PR not only for disorders of the arterial endothelium but also the microvasculature. The therapeutic targeting of S1PR in the endothelium could help to bridge the gap between biomedical research in vascular biology and clinical practice.
大量临床前研究表明,持续的内皮细胞激活显著导致组织水肿,使炎症反应持续存在,并加剧组织损伤,最终导致器官衰竭。然而,目前尚无旨在恢复内皮功能的特异性疗法。1-磷酸鞘氨醇(S1P)正成为内皮功能及内皮细胞对损伤反应的一种强效调节剂。最近的研究表明,S1P受体不仅是治疗动脉内皮疾病的有吸引力的靶点,也是治疗由缺血或炎症损伤引起的微血管功能障碍的有吸引力的靶点。在本文中,我们将综述目前关于S1P及其受体在健康和疾病状态下内皮功能中作用的认识,并讨论靶向S1P受体不仅针对动脉内皮疾病而且针对微血管系统的治疗潜力。在内皮细胞中对S1P受体进行治疗性靶向可能有助于弥合血管生物学的生物医学研究与临床实践之间的差距。